Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Proposal ofmyeloid Neoplasms with MYC -Positive Double Minutes As a Distinct Entity

Isolde Summerer, Wencke Walter, Manja Meggendorfer, Torsten Haferlach, Frank Dicker, Stephan Hutter, Niroshan Nadarajah, Constance Regina Baer, Anna Stengel, Wolfgang Kern, John M. Bennett, Claudia Haferlach, Christian Pohlkamp

Blood (2023) 142 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2023-189902

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Judith Neukirchen, MD, Heinz Tuechler, Matteo Giovanni Della Porta, MD, Pierre Fenaux, MD PhD, Ulrich Germing, MD, Agnès Guerci, Kathrin Nachtkamp, MD, Marianna Rossi, MD, Rosa Sapena, Wolfgang R. Sperr, MD, Corinna Strupp, MD, Aspasia Stamatoullas, MD, Peter Valent, MD, John M. Bennett, MD

Blood (2017) 130 (Supplement 1): 4259.

https://doi.org/10.1182/blood.V130.Suppl_1.4259.4259

Published: 2017

Journal Articles

Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F List, MD, Zhuoxin Sun, PhD, Amit Verma, MD, John M. Bennett, MD, Kathy L McGraw, PhD, Lisa Ann Nardelli, BS, Jaroslaw P Maciejewski, MD PhD FACP, Jessica K Altman, MD, Puneet Cheema, MD, David F. Claxton, MD, Rami S. Komrokji, MD, Selina Luger, MD, Ryan Mattison, MD, Tim Wassenaar, MD, Andrew Artz, MD, Charles A Schiffer, MD, Martin S. Tallman, MD

Blood (2016) 128 (22): 223.

https://doi.org/10.1182/blood.V128.22.223.223

Published: 2016

Journal Articles

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome

Megan Melody, BA, MS, Najla H Al Ali, Ling Zhang, MD, Hanadi Ramadan, BA, Eric Padron, MD, David Sallman, MD, Kendra L. Sweet, MD, Jeffrey E Lancet, MD, Alan F List, MD, John M. Bennett, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1985.

https://doi.org/10.1182/blood.V128.22.1985.1985

Published: 2016

Journal Articles

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Blood (2016) 128 (16): 2096–2097.

https://doi.org/10.1182/blood-2016-07-728766

Published: 2016

Journal Articles

Time-dependent changes in mortality and transformation risk in MDS

Blood (2016) 128 (7): 902–910.

https://doi.org/10.1182/blood-2016-02-700054

Published: 2016

Includes: Supplemental data

Journal Articles

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju-Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R. Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Blood (2016) 127 (12): 1551–1558.

https://doi.org/10.1182/blood-2015-07-657403

Published: 2016

Includes: Supplemental data

Journal Articles

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Chezi Ganzel, Larry D. Cripe, MD, Zhouxin Sun, Hugo F. Fernandez, MD, Peter A Cassileth, MD, Dan Douer, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Michael O'Connell, Peter H Wiernik, John M. Bennett, MD, Mark R Litzow, MD, Selina Luger, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1315.

https://doi.org/10.1182/blood.V126.23.1315.1315

Published: 2015

Journal Articles

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Blood (2015) 126 (23): 2879.

https://doi.org/10.1182/blood.V126.23.2879.2879

Published: 2015

Journal Articles

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Prerna Rastogi, MBBS, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Eric Padron, MD, Elizabeth M. Sagatys, MD, Mojdeh Naghashpour, MD, PhD, Jiangchuan Tao, MD, PhD, John M. Bennett, Alan List, MD, Jeffrey E Lancet, MD, Kenneth S. Zuckerman, MD, Ling Zhang, MD

Blood (2013) 122 (21): 4076.

https://doi.org/10.1182/blood.V122.21.4076.4076

Published: 2013

Journal Articles

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

Blood (2013) 122 (21): 1544.

https://doi.org/10.1182/blood.V122.21.1544.1544

Published: 2013

Journal Articles

A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)

Deniz Peker, MD, Eric Padron, MD, Pedro Horna, MD, John M. Bennett, MD, Xiaohui Zhang, MD, P.K. Epling-Burnette, PharmD, PhD, Jeffrey E Lancet, MD, Javier Pinilla, Lynn Moscinski, MD, Alan F. List, MD, Rami S. Komrokji, MD, Ling Zhang, MD

Blood (2012) 120 (21): 1712.

https://doi.org/10.1182/blood.V120.21.1712.1712

Published: 2012

Journal Articles

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Ranjana H. Advani, MD, Hailun Li, MS, Richard T. Hoppe, MD, Nancy L. Bartlett, MD, John M. Bennett, MD, Donna S. Neuberg, ScD, Peter A Cassileth, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 4779.

https://doi.org/10.1182/blood.V120.21.4779.4779

Published: 2012

Journal Articles

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop M. Kantarjian, MD, Ghulam J. Mufti, MD, Pierre Fenaux, MD, PhD, Mikkael A. Sekeres, MD, MS, Jeffrey Szer, MBBS, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, MD, PhD, Wieslaw Wiktor-Jedrzejczak, MD, PhD, John M. Bennett, MD, Anne Meibohm, PhD, Allen S. Yang, MD, PhD, Aristoteles Giagounidis, MD

Blood (2012) 120 (21): 421.

https://doi.org/10.1182/blood.V120.21.421.421

Published: 2012

Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD

Blood (2012) 120 (21): 3808.

https://doi.org/10.1182/blood.V120.21.3808.3808

Published: 2012

Journal Articles

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Blood (2012) 120 (12): 2454–2465.

https://doi.org/10.1182/blood-2012-03-420489

Published: 2012

Includes: Supplemental data

Journal Articles

Survival Analysis of Additional Chromosomal Aberrations in Philadelphia Chromosome Positive and Negative Cells: A Single Institutional

William Bulkeley, MD, Bijal D. Shah, MD, Monique A Hartley, MD, John M. Bennett, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Javier Pinilla

Blood (2011) 118 (21): 2523.

https://doi.org/10.1182/blood.V118.21.2523.2523

Published: 2011

NARROW

Proposal ofmyeloid Neoplasms with MYC -Positive Double Minutes As a Distinct Entity

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Time-dependent changes in mortality and transformation risk in MDS

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Survival Analysis of Additional Chromosomal Aberrations in Philadelphia Chromosome Positive and Negative Cells: A Single Institutional

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only